Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053800 | 1.00 | KMT2A (0.55) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL15547599 | 0.92 | ALOX15 (0.55) | KMT2AL3MBTL1FGFR1ALDH1A1ALOX15 | |
| Bromide SCHEMBL16050020 | 0.90 | ALOX15 (0.53) | KMT2AL3MBTL1FGFR1ALDH1A1MAPT | |
| SCHEMBL3361719 | 0.86 | KMT2A (0.53) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL24023413 | 0.85 | KMT2A (0.51) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL3199566 | 0.85 | KMT2A (0.51) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL7976424 | 0.85 | KMT2A (0.51) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL15547608 | 0.84 | KDM4E (0.53) | KMT2AALDH1A1MAPTALOX15ELANE | |
| SCHEMBL15548892 | 0.83 | GABRA1 (0.50) | KMT2ACA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL11263322 | 0.83 | KMT2A (0.50) | KMT2ACA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490612-A | Solid catalyst component for olefin polymerization, catalyst and application thereof | 中国石油化工股份有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-119490410-A | Ether ester compound, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2025-02-21 | — | — | CN | claimed |
| EP-3149135-A2 | PERFUME COMPOSITIONS | Givaudan S.A. (CH) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181257-A2 | PERFUME COMPOSITIONS | GIVAUDAN SA (CH) | 2015-12-03 | — | — | WO | claimed |
| EP-2237683-B1 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2015-11-11 | — | — | EP | claimed |
| CN-119930461-A | Preparation method of ferulic acid derivative, antibacterial effect of composition and application of composition in aspect of promoting plant growth | 贵州工业职业技术学院 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025082968-A1 | RIBONUCLEIC ACID-BASED MICROCAPSULES | FIRMENICH SA (CH) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025068225-A1 | MICROCAPSULES AND PROCESS FOR PREPARING MICROCAPSULES | FIRMENICH SA (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025068229-A1 | MICROCAPSULES AND PROCESS FOR PREPARING MICROCAPSULES | FIRMENICH SA (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-119490410-A | Ether ester compound, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-119490612-A | Solid catalyst component for olefin polymerization, catalyst and application thereof | 中国石油化工股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| WO-2009092176-A2 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | KMT2A 2697/4885CA12 2134/4885CA1 1475/4885 |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | PYM1, GPR119, GLP1R | KMT2A 1610/4885CA12 2479/4885CA1 2862/4885 |
| US-20090186138-A1 | Method of Flavoring | TAS2R5, TAS2R50, TAS2R10 | KMT2A 1234/4885CA12 1502/4885CA1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.